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Incipient tumor cells that escape intrinsic cellular mecha-
nisms of tumor suppression require support from the sur-
rounding stroma for their growth and ability to metastasize. 
The tumor-associated stroma provides vascular support and 
protumorigenic factors that can sustain tumor cell growth 
(Räsänen and Vaheri, 2010; Barcellos-Hoff et al., 2013). 
Similarly, at metastatic sites, such as in the bone microenvi-
ronment, tumor-activated osteoclasts and osteoblasts release 
bone-derived factors that favor tumor colonization and pro-
liferation (Weilbaecher et al., 2011). In addition to direct 
effects on tumor cells, the stromal compartment at primary 
and distal sites can indirectly contribute to tumor progres-
sion by supporting the development of an immunosuppres-
sive environment that facilitates tumor escape from immune 
control (Mace et al., 2013).
Cytotoxic T cells are central players in immune-mediated 
control of cancer, and the extent of tumor infiltration by cyto-
toxic T cells correlates with a favorable prognosis (Galon et al., 
2006; Hamanishi et al., 2007; Mahmoud et al., 2011; Bindea et 
al., 2013). However, this natural defense mechanism can be se-
verely blunted by immunosuppressive cell populations, includ-
ing regulatory T cells and myeloid suppressor cells (Schreiber et 
al., 2011; Gabrilovich et al., 2012). Among myeloid populations 
with a potent ability to suppress antitumor T cell responses, 
myeloid-derived suppressor cells (MDSCs) are found in high 
numbers in circulation and in the tumor microenvironment 
of patients with advanced malignancies (Gabitass et al., 2011). 
MDSCs comprise a heterogeneous population of immature 
Gr1+/CD11b+ cells in mice and CD33+/CD11b+ in humans 
(Gabrilovich et al., 2012). This myeloid population is further 
classified into granulocytic or monocytic MDSCs based on the 
expression levels of Ly6G and Ly6C, respectively, in the mouse 
model or CD15 and CD14 in humans.
Investigations into the mechanisms that drive MDSC 
recruitment and activity have shown that GM-CSF, IL-6, and 
VEGF play an important role via modulation of Jak–STAT 
signaling pathways (Gabrilovich et al., 2001; Trikha and Car-
son, 2014). In addition to Jak–STAT, we have recently shown 
that down-regulation of β-catenin in MDSCs is required for 
their accumulation during tumor progression in mice and 
cancer patients (Capietto et al., 2013). Specific deletion of 
β-catenin in myeloid cells leads to greater s.c. tumor growth 
due to the accumulation and higher immune suppressive ef-
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fects of MDSCs. Conversely, β-catenin stabilization in myeloid 
cells limits tumor growth by limiting MDSC numbers and 
their T cell suppressive function (Capietto et al., 2013). How-
ever, an outstanding question in the field is how β-catenin 
is down-regulated in MDSCs during tumor progression and 
whether the tumor-associated stromal compartment plays 
a role in this process.
Dickkopf-1 (Dkk1) is an inhibitor of the Wnt–β-catenin 
pathway (MacDonald et al., 2009). It competitively binds to 
the Wnt co-receptors LRP5/6, leading to degradation of the 
β-catenin complex. High circulating levels of Dkk1 correlate 
with poor prognosis in various cancers (Liu et al., 2014). In 
the context of multiple myeloma (MM), Dkk1, produced 
by the cancer cells and bone marrow stromal cells, inhibits 
osteoblast maturation while enhancing osteoclast resorp-
tion (Tian et al., 2003; Fowler et al., 2012). These effects 
of Dkk1 on the bone microenvironment contribute to the 
development of focal osteolytic lesions and indirectly favor 
MM progression. Increased levels of Dkk1 are also found in 
serologic samples from patients with cancer of the pancreas, 
stomach, liver, lung, esophagus, and breast, regardless of the 
presence of metastatic dissemination to bone (Yamabuki et 
al., 2007; Liu et al., 2014). These observations suggest more 
pleiotropic effects of Dkk1 in controlling tumor growth, in-
dependent of its ability to alter the bone microenvironment. 
Furthermore, down-regulation of β-catenin in cancerous 
cells should reduce their proliferative capacity. Therefore, it 
remains to be established why increased levels of Dkk1 cor-
relate with poor prognosis.
We now provide evidence that Dkk1 supports the gen-
eration of MDSCs, and thus is a negative regulator of anti-
tumor immune responses. Importantly, we show that Dkk1 
neutralization decreases tumor growth and MDSC accumu-
lation in extraskeletal tumor models. To our knowledge, this 
is the first demonstration that Dkk1 supports extraskeletal 
tumor growth by creating an immunosuppressive environ-
ment through direct targeting of β-catenin in MDSCs.
RES ULTS
Dkk1 is up-regulated in the bone microenvironment of 
mice bearing extraskeletal tumors
We have recently shown that down-regulation of β-catenin 
levels in MDSCs occurs in tumor-bearing mice and cancer 
patients. Reductions in β-catenin drive MDSC accumula-
tion in the bone marrow, spleen, and at primary tumor sites, 
and control their immune suppressive effects (Capietto et al., 
2013). To elucidate the mechanism(s) responsible for reduced 
β-catenin levels in MDSCs during tumor progression we 
measured the circulating levels of the Wnt/β-catenin inhibi-
tor Dkk1, because it has been associated with poor prognosis 
in various types of cancer (Liu et al., 2014). C57BL/6 WT 
mice were s.c. injected with 105 Lewis lung carcinoma (LLC) 
cells and serum was collected 0, 7, 10, and 14 d later. We 
found that circulating Dkk1 levels increased 20-fold, parallel-
ing tumor progression (Fig. 1 A).
Next, we wanted to determine the source of Dkk1 in 
tumor-bearing mice. Surprisingly, immunohistochemistry 
(IHC) analysis of LLC tumors revealed a weak and diffuse 
Dkk1 staining compared with pancreatic islets from mice 
with pancreatic adenocarcinomas, which we used as a posi-
tive control, or the ductal epithelium and stroma, which were 
negative and thus used as internal negative control (Fig. 1 B). 
This result was unexpected, given the significant increase in 
Dkk1 in circulation (Fig. 1 A), and prompted us to investigate 
other sources of Dkk1 in the LLC tumor-bearing mice.
Dkk1 is highly expressed in the bone microenviron-
ment by osteoblasts and osteocytes to regulate bone homeo-
stasis (Li et al., 2006; Pinzone et al., 2009). Because MDSCs 
originate and accumulate in the bone microenvironment 
during tumor progression, we wondered whether Dkk1 lev-
els would be increased in bones from tumor-bearing mice. 
First, we measured by quantitative RT-PCR Dkk1 transcripts 
in crushed bones devoid of bone marrow cells (as a source 
of osteoblasts and osteocytes), and in the bone marrow cells 
from LLC tumor-bearing mice. LLC tumors in vivo from the 
same cohort of mice and LLC cells cultured in vitro were 
used as controls. Confirming the IHC data, the LLC cell line 
did not express detectable Dkk1 transcripts. Strikingly, Dkk1 
mRNA levels in the crushed bones (devoid of marrow cells) 
were ∼500-fold higher compared with the tumor mass and 
the bone marrow cells (Fig. 1 C), suggesting that osteoblasts 
and osteocytes are a major source of Dkk1 in tumor-bearing 
mice. Because Dkk1 is a secreted protein, we measured Dkk1 
protein levels in the bone marrow interstitial fluid from LLC 
tumor-bearing mice by ELI SA to further confirm increased 
expression of bone-derived Dkk1 during tumor progression. 
We found a significant increase in bone-derived Dkk1 com-
pared with no tumor controls (Fig. 1 D).
To determine whether production of Dkk1 by the 
bone microenvironment is observed in other tumors, we 
turned to the B16 melanoma model, as β-catenin is also 
down-regulated in MDSCs from B16 tumor-bearing mice. 
Similar to mice bearing LLC tumors, increased Dkk1 levels 
were observed in circulation (Fig.  1  E) and in the bone 
microenvironment (Fig. 1, F and G) of animals injected s.c. 
with 105 B16 melanoma cells. RT-PCR analysis revealed 
no detectable Dkk1 expression in the tumor cells, and the 
transcript levels in the tumor mass in vivo were 340-fold less 
than in the bone (Fig. 1 F).
Finally, we analyzed Dkk1 mRNA expression in the 
bones of tumor-bearing mice (LLC and B16) versus primary 
osteoblasts or osteoclasts cultured in vitro (Fig. 1 H). We found 
a similar magnitude of expression between crushed bones and 
osteoblast cultures, whereas no expression was detected in the 
osteoclasts, suggesting that bone-resident osteoblasts, but not 
osteoclasts, are a major source of Dkk1 in vivo.
Collectively, these results demonstrate increased levels of 
Dkk1 in the circulation and in the bone microenvironment 
in two different tumor models, supporting the hypothesis that 
Dkk1 might regulate β-catenin levels in peripheral MDSCs.
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Dkk1 directly targets β-catenin in MDSCs
Dkk1 antagonizes canonical Wnt signaling by binding to 
LRP5/6 receptors and inhibiting their interaction with 
Wnt ligands. To evaluate whether Dkk1 can directly target 
MDSCs, we first measured LRP5 and LRP6 expression lev-
els in Gr1+/CD11b+ cells isolated from tumor naive mice 
or animals bearing s.c. LLC tumors. Both receptors were 
highly expressed in MDSCs from tumor-bearing mice com-
pared with control mice (Fig. 2 A). Induction of LRP5 and 
LRP6 transcripts was also observed in naive Gr1+/CD11b+ 
cells cultured in vitro in the presence of 10% serum from 
tumor-bearing mice to mimic the in vivo setting (Fig. 2 B).
To test whether Dkk1 directly affects β-catenin protein lev-
els in MDSCs, naive Gr1+/CD11b+ cells were isolated from the 
bone marrow, cultured as described in the Materials and meth-
ods, and stimulated for 3 h with recombinant Dkk1 (rDkk1; 100 
ng/ml). Because Dkk1 is elevated in the serum of tumor-bearing 
mice (Fig. 1 A), which was added to the culture medium, we also 
incubated the cells with anti-Dkk1 (100 ng/ml), an exercise that 
would establish the importance of circulating Dkk1 in regulating 
β-catenin. Dkk1 neutralization resulted in increased β-catenin 
protein levels in the cells (Fig. 2 C). In contrast, treatment with 
rDkk1 reduced β-catenin protein levels compared with controls 
(Fig.  2  C). Confirming these findings, quantitative RT-PCR 
analysis of β-catenin target genes showed a significant reduction 
of LEF1, TCF4, and Axin2 mRNA expression levels after rDkk1 
stimulation versus untreated controls (Fig. 2 D).
To determine whether Dkk1 reduces β-catenin levels 
in human MDSCs, CD33+ myeloid cells were isolated from 
PBMCs obtained from different healthy donors and cultured 
in the presence of serum from cancer patients with elevated 
Dkk1 levels. Cells were incubated with anti-Dkk1 or stimu-
lated with rDkk1, and mRNA levels of the β-catenin target 
genes TCF4 and LEF1 were measured. Similar to the mouse 
model, we found that rDkk1 reduced the expression of TCF4 
and LEF1 (Fig. 2, E and F), whereas neutralization of Dkk1 
Figure 1. Dkk1 is up-regulated in mice bearing extraskeletal tumors. (A) Dkk1 serum levels were measured by ELI SA in WT mice on day 0 or 7, 10, 
and 14 d after LLC s.c. injection. n = 4 per group. *, P < 0.05; **, P < 0.01; ***, P < 0.001. Experiment was repeated two times. (B) IHC from mouse pancreatic 
ductal adenocarcinoma (CTR) or LLC s.c. tumor sections stained for Dkk1. Images are taken with an 20× objective (left) and 2× magnification is shown on 
the right. Data are representative of four different tumor sections. (C) Dkk1 mRNA levels were measured in LLC in vitro, LLC tumor mass, crushed bones 
devoid of marrow cells, and bone marrow cells isolated from WT mice 2 wk after s.c. tumor injection. Data are expressed as relative expression to cyclophillin. 
Results represent mean ± SD (n = 6, experiment repeated three times). **, P < 0.01; ***, P < 0.001. (D) Dkk1 levels in the bone marrow interstitial fluid of LLC 
tumor–bearing mice versus no tumor controls collected 2 wk after s.c. tumor injection. *, P < 0.05. n = 6. Experiment was performed in duplicate. (E) Dkk1 
levels in circulation from WT mice prior, 7, or 14 d after s.c. inoculation of 105 B16 cells. *, P < 0.05; ***, P < 0.001. n = 5. Experiment performed in duplicate. 
(F) Dkk1 mRNA levels were measured in B16 cell line, tumor mass, crushed bones devoid of bone marrow cells, and in the bone marrow 14 d after B16 s.c. 
tumor injection. *, P < 0.05; ***, P < 0.001. n = 5. Experiment was repeated more than three times. (G) Dkk1 levels in the bone marrow interstitial fluid from 
WT mice prior and 14 d after s.c inoculation of 105 B16 cells. *, P < 0.05. n = 6. Experiment was performed in duplicate. (H) Dkk1 mRNA levels were measured 
in crushed bones separated from the bone marrow of mice inoculated s.c. with LLC or B16 for 14 d, in osteoblast cultures and primary osteoclasts. n = 3. 
Experiment was repeated three times.
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resulted in the up-regulation of the two β-catenin target 
genes in human cells (Fig. 2, G and H). Thus, Dkk1 inhibits 
the β-catenin pathway both in mouse and human MDSCs.
Dkk1 expression correlates with MDSC 
accumulation in cancer patients
Having demonstrated that Dkk1 directly targets β-catenin 
signaling in MDSCs from both mice and humans, we next 
wanted to determine whether increased Dkk1 expression is 
associated with MDSC accumulation in cancer patients. El-
evated levels of Dkk1 have been observed in serum and at 
the primary tumor sites in pancreatic cancer. Previous stud-
ies have also shown that pancreatic cancer patients have ex-
panded CD15+ MDSC populations (Porembka et al., 2012). 
We further demonstrated that MDSCs isolated from these pa-
tients have decreased β-catenin levels compared with healthy 
Figure 2. Dkk1 targets β-catenin in MDSCs and 
correlates with CD15 myeloid marker. (A and B) 
LRP5 and LRP6 mRNA expression in MDSCs isolated 
from LLC tumor-bearing mice 14 d after tumor in-
jection (A), or in Gr1+/CD11b+ naive cells incubated in 
vitro in the presence or absence of 10% serum from 
tumor-bearing mice (B). Mean ± SD (n = 3 mice/
group) *, P < 0.05; **, P < 0.01. (C) Western blot anal-
ysis of β-catenin in Gr1+/CD11b+ naive cells cultured 
for 6  h in medium containing 10% serum from tu-
mor-bearing mice in the presence of rDkk1 (100 ng/
ml) or anti-Dkk1 (100 ng/ml). One representative ex-
periment of three is shown. (D) LEF1, TCF4, and Axin2 
mRNA levels were measured in cells as in B. Mean ± 
SD from three independent experiments. *, P < 0.05. 
(E–H) LEF1 and TCF4 mRNA levels were measured in 
CD33+ PBMCs isolated from healthy donors, cultured 
in the presence of 10% serum from cancer patients 
and stimulated in vitro with rDkk1 (100 ng/ml; E and 
F) or incubated with anti-Dkk1 (100 ng/ml; G and H). 
Representative graphs from seven different donors 
are shown. Experiment was repeated more than three 
times. (I) Representative IHC from pancreatic cancer 
tissues with high or low Dkk1 expression is shown. 
CD15 staining, as a marker of granulocytic MDSCs, is 
also shown. (J) Correlation between CD15+ cell num-
bers and Dkk1 pixel density from 55 pancreatic cancer 
tissues is shown (Spearman’s r = 0.27; P = 0.04).
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donors (Capietto et al., 2013), thus making this tumor model 
highly relevant for studying a possible correlation between 
Dkk1 expression and MDSC accumulation. To test our hy-
pothesis, we obtained tissue microarrays (TMAs) from 55 
T1-T3 and stage I-II tumor tissues from pancreatic cancer 
patients with no metastatic disease. The TMAs were blindly 
scored for the presence of CD15+ infiltrates and Dkk1 expres-
sion. We found tumor tissues with high Dkk1 expression both 
in the tumor cells and in the associated tumor stroma, and 
others with low Dkk1 expression (Fig. 2 I). Nevertheless, we 
observed that accumulation of CD15+ cells significantly cor-
related with increased Dkk1 expression (Spearman’s r = 0.27; 
P < 0.05; Fig.  2  J). Future studies are required to measure 
Dkk1 expression in the bone microenvironment and cor-
relate this result with peripheral MDSCs. Collectively, these 
findings support the hypothesis that Dkk1 induces MDSC 
accumulation during tumor progression.
Dkk1 neutralization decreases tumor 
growth and MDSC numbers
To demonstrate that Dkk1 contributes to MDSC accumu-
lation in vivo by reducing β-catenin levels in these cells, 
WT mice were s.c. injected with 105 LLC, a tumor cell 
line which induces up-regulation of Dkk1 and increases 
MDSC numbers during tumor progression (Fig. 1; Capietto 
et al., 2013). Tumor-bearing mice were then administered 
anti-Dkk1 or IgG as a control (20 mg/kg) three times per 
week for 2 wk. Strikingly, we observed a significant decrease 
in tumor growth and size after anti-Dkk1 treatment com-
pared with IgG control (Fig.  3, A and B). In support of 
our hypothesis, the percentages of Gr1+/CD11b+ MDSCs 
in the bone marrow, spleen, and tumor were significantly 
reduced (Fig.  3 C), and β-catenin expression was rescued 
in MDSCs isolated from anti-Dkk1–treated mice compared 
with IgG controls (Fig. 3 D).
MDSCs are potent suppressors of antitumor T cell re-
sponses. To determine whether Dkk1 neutralization is suf-
ficient to restore T cell infiltration in the tumor stroma, we 
measured by FACS the percentage of CD4+ and CD8+ T cells 
in the tumor-bearing mice treated every other day with the 
anti-Dkk1. Consistent with a reduction in MDSC numbers, 
we found that the percentages of CD4+ and CD8+ T cells were 
increased in anti-Dkk1–treated mice versus controls (Fig. 3 E).
MDSCs have been shown to increase with tumor bur-
den in several models. Therefore, to ask if changes in MDSCs 
were caused by Dkk1 levels and not primary tumor size, we 
examined MDSCs in anti-Dkk1–treated and IgG control 
mice that were sacrificed 7 d after tumor injection, when 
no detectable differences in tumor growth were yet observed 
(Fig.  3  F). Confirming the similar tumor size detected by 
caliper measurements, the weight of the excised tumors was 
not different between the two groups (Fig. 3 F). Neverthe-
less, a significant decrease in MDSC percentage was already 
evident at this time point in the bone marrow, spleen, and 
tumor site (Fig. 3 G). These data indicate that the effects of 
anti-Dkk1 on MDSCs precede the effects of the neutralizing 
antibody on tumor growth.
Because we found that Dkk1 levels were elevated in cir-
culation and in the bone microenvironment of mice bearing 
B16 tumors (Fig. 1, E and G), we next asked if Dkk1 neu-
tralization could also exert antitumor effects in this model. 
Indeed, anti-Dkk1 was sufficient to significantly reduce B16 
subcutaneous tumor growth (Fig.  3  H). As with the LLC 
tumor model, the percentage of MDSCs was significantly 
reduced in the bone marrow and spleen by the anti-Dkk1 
treatment (Fig. 3 I). Together, these data show that Dkk1 neu-
tralization reduces tumor growth and MDSC accumulation 
during tumor progression.
Dkk1 neutralization affects tumor progression 
in advanced cancer models
To further exploit the therapeutic effects of anti-Dkk1 
treatment, we administered anti-Dkk1 to WT mice bearing 
established s.c. tumors with already expanded MDSC pop-
ulation. 1 wk after 105 LLC s.c. injection, animals received 
anti-Dkk1 or IgG control antibodies (20 mg/kg every other 
day) for an additional 7 d. We observed a significant de-
crease in tumor growth (Fig. 4, A and B) and concomitant 
reduction in MDSC percentage in the bone marrow, spleen, 
and tumor site of anti-Dkk1–treated mice compared with 
IgG controls (Fig. 4 C).
To determine whether Dkk1 neutralization would 
exert significant antitumor effects in a mouse model of 
pre-expanded MDSCs, we turned to PLCγ2−/− mice. We re-
cently demonstrated that PLCγ2-null animals have increased 
MDSC numbers and, in these mice, MDSCs are responsible 
for the higher rate of tumor growth compared with WT mice 
(Capietto et al., 2013). Most importantly, similarly to the can-
cer patients, MDSCs from PLCγ2−/− mice have significantly 
lower β-catenin levels than WT MDSCs (Capietto et al., 
2013). Consistent with this observation, Dkk1 is significantly 
up-regulated in the bone microenvironment of PLCγ2−/− 
tumor-bearing mice compared with controls (Fig.  4  D). 
To investigate whether Dkk1 neutralization would protect 
PLCγ2−/− mice from tumor progression by reducing MDSC 
numbers, 105 LLC cells were s.c. injected into PLCγ2−/− an-
imals after the administration of anti-Dkk1 or IgG for 14 d. 
Strikingly, Dkk1 neutralization dramatically reduced tumor 
growth and percentage of MDSCs in the bone marrow, 
spleen, and tumor site compared with IgG controls (Fig. 4, 
E and F). Confirming that Dkk1 directly targets PLCγ2−/− 
MDSCs, β-catenin levels in these cells were rescued by Dkk1 
neutralization (Fig.  4 G). Importantly, the anti-Dkk1 treat-
ment also affected MDSC functionality, as shown by a signif-
icant reduction in reactive oxygen species (ROS) and nitric 
oxide (NO) production in PLCγ2−/− MDSCs isolated from 
anti-Dkk1–treated mice compared with MDSCs from IgG 
controls (Fig. 4, H and I).
Together, these results indicate that anti-Dkk1 reduces 
established tumor growth and exerts antitumor effects in 
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mouse models of preexpanded MDSCs by decreasing MDSC 
numbers and functionality.
MDSCs are a direct target of anti-Dkk1 treatment
To determine whether Dkk1 neutralization reduces tumor 
growth by increasing β-catenin levels in MDSCs, and not 
by targeting other cell populations, we analyzed the effects 
of anti-Dkk1 treatment in β-catenin–floxed mice express-
ing the Cre recombinase under the control of Lysozyme M 
(LysM-Cre/β-cateninflox/flox; herein defined as βcatcKo). We 
previously demonstrated that MDSCs from βcatcKo mice do 
not express β-catenin (Capietto et al., 2013). LLC cells were 
injected s.c. into βcatcKo animals, followed by anti-Dkk1 or 
IgG treatment, three times a week for 2 wk. Tumor growth 
was followed by caliper measurements at indicated days and 
the tumor mass was resected and weighed. In contrast to WT 
mice, anti-Dkk1 treatment did not affect the growth or size 
of the LLC tumors (Fig.  5 A, B); more importantly, Dkk1 
neutralization did not reduce the percentage of MDSCs 
in the bone marrow, spleen, or tumor site of βcatcKo ani-
Figure 3. Dkk1 neutralization decreases tumor growth and MDSC expansion. (A) Anti-Dkk1 or IgG control antibodies (20 mg/kg, three times per 
week) were administered for 2 wk into WT mice s.c. injected with 105 LLC cells. Tumor growth was evaluated by caliper measurements at indicated days. 
Mean ± SD (n = 7) is shown. Data are reported from one of three similar independent experiments. *, P < 0.05; **, P < 0.01. (B) 14 d after tumor injection, 
the tumors shown in A were resected. One representative image is shown. (C) Percentage of MDSCs in the bone marrow, spleen, and tumor was analyzed by 
FACS using anti-Gr1 and anti-CD11b staining. Results represent means ± SD (n = 7). One representative experiment of three is shown. *, P < 0.05. (D) MDSCs 
were isolated from the bone marrow of no tumor or tumor-bearing WT mice receiving IgG control or anti-Dkk1 treatment and subjected to Western blot 
analysis to measure β-catenin protein levels. β-Actin was used as loading control. One representative Western blot from three independent experiments 
is shown. (E) CD4+ and CD8+ T cell percentage was analyzed by FACS in excised tumors from WT mice treated with anti-Dkk1 or IgG control. Bar graphs 
show mean ± SD (n = 7). *, P < 0.05. One representative experiment of three is shown. (F) WT mice s.c. inoculated with 105 LLC cells were treated with an-
ti-Dkk1 or IgG control starting 1 wk after tumor inoculation. After 7 d of treatment, the animals were sacrificed and the tumor was resected and weighed. 
Results represent mean ± SD (n = 5). (G) Percentage of MDSCs (Gr1+/CD11b+) from bone marrow, spleen, and tumor of mice in F were then analyzed by 
FACS staining. Results represent mean ± SD (n = 5). *, P < 0.05. (H) Tumor growth in mice inoculated with 105 B16 cells treated with IgG or anti-Dkk1 was 
evaluated by caliper measurements for the indicated days. Mean ± SD (n = 5) is shown. Data reported from one of three similar independent experiments. 
**, P < 0.01. (I) Percentage of Gr1+/CD11b+ MDSC from bone marrow and spleen of mice treated as in H were analyzed by FACS staining. Results represent 
mean ± SD (n = 5). **, P < 0.01.
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mals (Fig.  5  C). Consistent with our previous observation 
showing that the expression of a constitutively active form 
of β-catenin in myeloid cells limits tumor growth by re-
ducing MDSC numbers and functionality (Capietto et al., 
2013), we now demonstrate that Dkk1 neutralization exerts 
profound antitumor effects by restoring β-catenin levels in 
the myeloid compartment.
To further establish that the Dkk1-neutralizing anti-
body targets MDSCs, and not other immune cell populations, 
we injected 105 LLC into WT mice receiving anti-Gr1 (12.5 
mg/kg) to deplete MDSCs in the presence or in the absence 
of anti-Dkk1. Mice receiving IgG were used as controls. As 
shown previously, anti-Gr1 exerts significant antitumor ef-
fects (Mundy-Bosse et al., 2011). The reduction in tumor 
growth after anti-Gr1 treatment was similar to that observed 
in mice treated with anti-Dkk1 (Fig. 5 D). No further de-
crease in tumor growth was noted in mice receiving both 
anti-Gr1 and anti-Dkk1 compared with each treatment alone 
(Fig.  5  D). Consistent with our hypothesis that anti-Dkk1 
targets MDSCs, Dkk1 neutralization induced a similar re-
duction in the percentage of MDSCs at tumor site to that 
observed in mice treated with anti-Gr1 alone or anti-Gr1 
plus anti-Dkk1 (Fig. 5 E). These results demonstrate that the 
antitumor effects of Dkk1 neutralization overlap with those 
of the anti-Gr1, further implicating Dkk1 as an important 
regulator of tumor-induced MDSCs.
Dkk1 controls MDSC immune suppressive effects
Because one of the best-characterized functions of MDSCs is 
to actively suppress cytotoxic T cell responses, we examined 
whether T cells were important players in mediating the an-
titumor effects of the anti-Dkk1. To this end, we injected 105 
LLC cells s.c. into Nude mice, which lack T cell populations, 
and administered anti-Dkk1 or IgG antibodies as described in 
Figure 4. Dkk1 neutralization reduces tumor progression in tumor models of preexpanded MDSCs. (A and B) 105 LLC cells were s.c. injected in WT 
mice and anti-Dkk1 and IgG treatments (20 mg/ml) were administered 7 d after tumor inoculation and treated for seven additional days. Tumor growth 
was assessed by caliper measurements. Mean ± SD (n = 5) is shown. *, P < 0.05. (B) Representative image of tumors as shown in A. (C) Percentage of Gr1+/
CD11b+ MDSCs isolated from bone marrow, spleen, and tumor of mice treated as in A was determined by FACS. Results represent means ± SD (n = 5). *, P < 
0.05. (D) Dkk1 mRNA expression in crushed bones devoid of bone marrow cells of PLCγ2−/− mice s.c. injected with 105 LLC cells. Mean ± SD (n = 5) is shown. 
**, P < 0.01. (E) Tumor growth in PLCγ2−/− mice injected s.c. with 105 LLC cells and treated with anti-Dkk1 or IgG control (20 mg/kg) three times per week 
for 2 wk starting at time of LLC injection. Tumor size was determined by caliper measurements. n = 4, representative of three independent experiments. *, P 
< 0.05; **, P < 0.01. (F) Percentage of Gr1+/CD11b+ MDSCs isolated from bone marrow, spleen, and tumor of mice treated as in E was determined by FACS. 
Mean ± SD. n = 4; representative of three independent experiments. *, P < 0.05. (G) β-Catenin protein levels were measured by Western blot in PLCγ2−/− 
MDSCs isolated from the bone marrow of no tumor or tumor-bearing mice after IgG and anti-Dkk1 treatment. β-Actin was used as loading control. One 
representative Western blot is shown. (H and I) ROS and NO levels measured in PLCγ2−/− MDSCs isolated from tumor-bearing mice treated with anti-Dkk1 
or IgG as control. Data are reported from one of two independent experiments. Mean from biological triplicates ± SD. *, P < 0.05; **, P < 0.01.
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the Materials and methods. We found no differences in tumor 
growth between anti-Dkk1 and IgG control-treated mice at 
late stages of tumor progression (Fig. 6 A). This finding indi-
cates that T cells are required for anti-Dkk1 long-term anti-
tumor effects, leading to the hypothesis that Dkk1 targeting 
may reduce MDSC immune suppressive functions.
ROS production is one of the mechanisms attributed 
to MDSC ability to suppress T cell responses. To determine 
whether Dkk1 directly affects MDSC functionality, we mea-
sured ROS levels in MDSCs isolated from WT mice and 
stimulated in vitro with rDkk1 (1 µg/ml). Consistent with 
our hypothesis, rDkk1 significantly increased ROS produc-
tion by MDSCs (Fig. 6 B).
Next, to test whether anti-Dkk1 treatment impacts 
MDSC functionality, we examined the ability of MDSCs 
isolated from tumor-bearing mice treated with anti-Dkk1 
or IgG to suppress T cell proliferation ex vivo. CSFE-labeled 
splenocytes from naive WT mice were incubated with an-
ti-CD3 (10 µg/ml) to induce mitogen-driven CD8+ T cell 
proliferation in the presence of MDSCs isolated from tumor- 
bearing mice treated with anti-Dkk1 or IgG control. Three 
different ratios of MDSCs/splenocytes (1:10, 1:5, and 1:1) 
were tested and proliferation of targeted CD8+ T cells was 
measured in terms of CFSE dilution by FACS analysis 72 h 
later. MDSCs isolated from anti-Dkk1–treated WT mice dis-
played reduced T cell immune suppressive effects compared 
with MDSCs from IgG controls (Fig. 6 C). Consistent with 
the in vitro observations, increased percentage of T cells in 
the spleen and primary tumor was also observed in vivo in 
tumor-bearing WT mice after treatment with anti-Dkk1 
(Fig. 6 D and 3 E). To further evaluate whether the number 
of activated T cells is also increased upon treatment with anti- 
Dkk1, we measured the percentage of activated CD44hi 
CD62Llow and memory CD44hiCD62Lhi, splenic CD4+ and 
CD8+ T cells in WT mice 14 d after tumor injection. Our 
data show higher percentage of activated and memory T cells 
in mice treated with anti-Dkk1 (Fig. 6, E and F).
As previously shown, PLCγ2−/− MDSCs have very 
strong immunosuppressive effects (Capietto et al., 2013). 
Treatment with anti-Dkk1 significantly reduced PLCγ2−/− 
MDSC ability to suppress T cell proliferation ex vivo 
(Fig. 6 G), and increased CD4+ and CD8+ T cell percent-
ages in the spleen of PLCγ2−/− tumor-bearing mice in vivo 
(Fig. 6 H). These results are consistent with reduced ROS 
and NO levels observed in PLCγ2−/− MDSCs isolated from 
anti-Dkk1–treated mice (Fig. 4 H, I).
In contrast, Dkk1 neutralization did not affect the im-
munosuppressive capacities of βcatcKo MDSCs, as shown by 
a similar T cell proliferation rate by βcatcKo MDSCs isolated 
from IgG and anti-Dkk1–treated mice (Fig. 6 I). In agree-
ment with the in vitro findings, anti-Dkk1 treatment failed 
to increase the T cell percentage in the spleen of tumor- 
bearing βcatcKo (Fig. 6 J).
Collectively, these results indicate that Dkk1 exerts im-
mune suppressive effects by targeting β-catenin levels in 
MDSCs, thus controlling MDSC accumulation and their ability 
to suppress T cell activation and proliferation.
DIS CUS SION
This study demonstrates that Dkk1, an antagonist of the 
Wnt–β-catenin pathway, supports tumor progression by cre-
ating an immune suppressive environment where tumor cells 
can grow unabated. We show that Dkk1 neutralization con-
fers protection from tumor growth by reducing the gener-
ation and the T cell suppressive effects of MDSCs. To our 
Figure 5. Dkk1 neutralization loses its antitumor effects in βcatcko 
mice and after MDSC depletion. (A and B) 105 LLC cells were s.c. injected 
in βcatcKo mice and anti-Dkk1 or IgG as control (20 mg/kg) were admin-
istered three times per week. Tumor growth was followed by caliper mea-
surements (A) and, 2 wk later, tumors were resected and weighed (B). Mean 
± SD (n = 8). Data are reported from one of two independent experiments. 
n.s., not significant. (C) Percentage of Gr1+/CD11b+ MDSCs isolated from 
bone marrow, spleen, and tumor of mice in A was determined by FACS. Re-
sults represent means ± SD (n = 8). One representative experiment of two 
is shown. n.s., not significant. (D) 105 LLC cells were s.c. injected in WT mice, 
and IgG, anti-Dkk1 (20 mg/kg), anti-Gr1 (12.5 mg/kg), or anti-Dkk1 plus 
anti-Gr1 were administered three times per week. Tumor growth was fol-
lowed by caliper measurements. Mean ± SD (n = 6/7 mice group). P-values 
are shown in table. (E) Percentage of Gr1+/CD11b+ MDSCs in tumors from 
mice treated as in D was determined by FACS. Results represent means ± 
SD (n = 6/7). *, P < 0.05; ***, P < 0.001. n.s., not significant.
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knowledge, this is the first study demonstrating that MDSCs 
are a direct target of Dkk1, thus providing new insights as to 
why elevated circulating levels of Dkk1 correlate with poor 
prognosis in cancer patients.
In bone, Dkk1 negatively regulates osteoblast differenti-
ation and enhances osteoclast formation, and therapies aimed 
at targeting Dkk1 are in consideration for post-menopausal 
osteoporosis (Zhang and Drake, 2012). High levels of Dkk1 
are also observed in various cancer patients without detect-
able metastases to bone (Yamabuki et al., 2007; Liu et al., 
2014). However, the mechanism by which Dkk1 exerts its 
protumorigenic effects has not been elucidated. Studies in 
MM indicate that Dkk1 changes the bone microenvironment 
by creating a hospitable niche that allows dissemination and 
proliferation of tumor cells (Fowler et al., 2012). Interest-
ingly, although administration of anti-Dkk1 reduces tumor 
burden in vivo, the growth of MM cells is not affected in 
vitro, suggesting that the bone microenvironment is the tar-
get of the anti-Dkk1 treatment rather than the MM tumor 
cells (Yaccoby et al., 2007). In support of this assumption, 
Dkk1 is found to be highly expressed by bone marrow stro-
mal cells and knockdown of Dkk1 in these cells decreases 
myeloma progression in mice (Fowler et al., 2012). These 
studies support a model in which Dkk1 produced by bone 
marrow stromal cells induces the activation of bone resorb-
ing osteoclasts and the release of tumor-promoting factors 
stored in the bone matrix that favor MM growth. However, 
although it is certainly possible that osteoclasts mediate Dkk1 
protumor effects through the release of latent factors present 
in the bone matrix, this model does not explain why elevated 
Dkk1 levels correlate with poor prognosis in cancer patients 
with no detectable tumors in bone. Regulation of extraskele-
tal tumors by resorbing osteoclasts needs to be further investi-
gated. Pharmaceutical activation of bone resorbing osteoclasts 
enhances breast cancer growth in bone, but not outside the 
bone (Yang et al., 2013). Similarly, RAN KL, a potent stimula-
tor of osteoclastogenesis, increases prostate cancer cell growth 
in bone but not in soft tissues (Zheng et al., 2014). These data 
suggest that the Dkk1’s protumor effects may not be solely 
related to its ability to enhance osteoclast activities.
Our work demonstrates a previously unidentified im-
mune modulatory role for Dkk1 as a key player in the accumu-
lation and activation of immunosuppressive myeloid cells. By 
Figure 6. Neutralization of Dkk1 decreases MDSC immune suppres-
sive activity. (A) 105 LLC cells were s.c. injected in Nude mice and an-
ti-Dkk1 or IgG as control (20 mg/kg) were administered three times per 
week. Tumor growth was followed by caliper measurements. Mean ± SD 
(n = 8). *, P < 0.05. (B) ROS production in Gr1+/CD11b+ cells from naive 
WT mice and stimulated in vitro with rDkk1 for 24  h. Bar graphs show 
mean ± SD of biological triplicates. Representative of two independent ex-
periments. **, P < 0.01. (C) MDSCs, isolated from WT tumor-bearing mice 
treated with anti-Dkk1 or IgG, were co-cultured for 3 d with CFSE-labeled 
splenocytes from naive mice in the presence of anti-CD3 (10 µg/ml). CD8+ T 
cell proliferation was measured in terms of CFSE dilution. Bar graphs show 
mean ± SD of three independent experiments. *, P < 0.05. (D) Percent-
age of CD4+ and CD8+ T cells isolated from the spleen of WT tumor-bear-
ing mice treated with anti-Dkk1 or IgG as control was analyzed by FACS. 
Bar graphs show mean ± SD. n = 7. *, P < 0.05. (E and F) Percentage of 
CD44highCD62Llow or CD44highCD62Lhigh CD4+ and CD8+ T cells in spleen of 
WT tumor-bearing mice after anti-Dkk1 and IgG treatment was measured 
by FACS. Bar graphs show mean ± SD (n = 7). *, P < 0.05. (G) CD8+ T cell 
proliferation assay was performed as in C using WT splenocytes co-cul-
tured with PLCγ2−/− MDSCs. Bar graphs show mean ± SD of three inde-
pendent experiments. *, P < 0.05. (H) Percentage of CD4+ and CD8+ T cells 
in spleen of PLCγ2−/− tumor-bearing mice after anti-Dkk1 or IgG treatment 
was measured by FACS. Bar graphs show mean ± SD (n = 3, representative 
of three independent experiments). *, P < 0.05. (I) CD8+ T cell proliferation 
assay as in C in the presence of βcatcKo MDSCs isolated from anti-Dkk1 
and IgG antibody-treated mice. Bar graphs show mean ± SD. n = 3. (J) Per-
centage of CD4+ and CD8+ T cells in spleen of βcatcKo tumor-bearing mice 
after anti-Dkk1Ab and IgG treatment was measured by FACS. Bar graphs 
show mean ± SD (n = 8), representative of two independent experiments.
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using extraskeletal tumor models consisting of mice injected 
subcutaneously with LLC or B16 tumor lines, we report that 
neutralization of Dkk1 reduces tumor growth, limits MDSC 
expansion, decreases MDSC immune suppressive effects and, 
in turn, increases T cell numbers and activation in the spleen 
and primary tumor. Importantly, we further demonstrate 
that Dkk1 neutralization reduces growth of established tu-
mors and also exerts potent antitumor effects in mice lacking 
PLCγ2, which have increased numbers of MDSCs.
Decreased PLCγ2 and β-catenin levels have been 
previously observed in patients with advanced cancer (Ca-
pietto et al., 2013). Mice lacking PLCγ2 have expanded 
MDSC numbers with very low β-catenin expression, and 
tumor growth is increased compared with WT animals. As 
a consequence of the significant MDSC accumulation and 
activation, PLCγ2−/− mice have impaired antitumor T cell 
responses; however, adoptive T cell transfer has only limited 
antitumor effects in these animals (Zhang et al., 2011), sug-
gesting that MDSCs establish a very strong immune suppres-
sive environment in these animals. We now demonstrate that 
neutralization of Dkk1 exerts significant antitumor effects 
in PLCγ2−/− mice by reducing MDSC accumulation and 
functionality and consequently increasing the percentage of 
T cells. This finding, in conjunction with the protective effect 
of anti-Dkk1 treatment on established tumors, suggests that 
an anti-Dkk1 could potentially be a useful antitumor therapy 
for advanced cancer patients. Previous studies have shown ex-
panded CD15+ MDSC population (Porembka et al., 2012) 
with reduced β-catenin levels (Capietto et al., 2013) in pan-
creatic cancer. We now find a correlation between Dkk1 levels 
and tumor-infiltrating CD15+ cells in these patients. Further 
studies, however, are needed to determine whether bone- 
derived Dkk1 might have a stronger correlation with MDSC 
numbers and if Dkk1 induces CD15+ cell accumulation in 
other types of cancer, where Dkk1 levels are low at tumor site.
The finding that an anti-Dkk1 suppresses growth 
of tumors residing outside the bone is an important ob-
servation. β-catenin is a known regulator of tumor cell 
proliferation. Systemic administration of anti-Dkk1 in tumor- 
bearing mice could, therefore, also target the tumor cells 
and enhance their proliferation by increasing β-catenin ex-
pression. Although certainly possible for some tumors more 
strictly dependent on β-catenin levels for their growth, our 
data demonstrate that restoring the expression of β-catenin 
in myeloid cells and, more specifically, in MDSCs, is suf-
ficient to exert potent antitumor effects. These findings 
are in agreement with the tumor phenotype of mice ex-
pressing a nondegradable form of β-catenin in myeloid 
cells, which are protected from tumor growth as a result of 
limited MDSC expansion (Capietto et al., 2013). Similarly, 
we now show that Dkk1 neutralization increases β-catenin 
expression in MDSCs and limits their ability to suppress 
T cell proliferation. Importantly, the antitumor effects of the 
neutralizing antibody are lost in mice lacking β-catenin in 
myeloid cells. These data demonstrate that the antitumor ef-
fects of systemic anti-Dkk1 administration are mediated by 
the myeloid compartment.
We propose that MDSCs are the primary target of Dkk1. 
MDSCs express LRP5/6 co-receptors. Induction of LRP5 
and LRP6 transcripts is also observed in naive bone marrow–
derived Gr1+/CD11b+ cells cultured in vitro in the presence 
of 10% serum from tumor-bearing mice. Most importantly, 
these cells respond to rDkk1 with reduced β-catenin pro-
tein levels and β-catenin target gene expression. Although we 
don’t currently know whether additional factors present in 
the serum from the tumor-bearing mice are required to sup-
port a more robust response to rDkk1 in vitro, most likely 
increased expression of the Dkk1 target receptors LRP5 and 
LRP6 mediates these effects. Similar to the mouse model, 
rDkk1 also directly targets human MDSCs by decreasing 
mRNA expression levels of β-catenin target genes, which are 
restored upon depletion of Dkk1 from the serum of cancer 
patients. Furthermore, we also show that Dkk1 neutralization 
does not exert additional antitumor effects in mice treated 
with an anti-Gr1 to deplete MDSCs, suggesting that the two 
antibodies target the same myeloid population. Notably, anti- 
Dkk1 and anti-Gr1 treatments induce a similar reduction in 
tumor growth and MDSC numbers.
Whereas MDSCs are certainly a direct target of Dkk1, 
we also observe that anti-Dkk1 antitumor effects depend on 
T cells. Indeed, Dkk1 neutralization fails to reduce tumor 
growth in Nude mice that lack T cells. This result, together 
with the loss of antitumor effects in βcatcKo mice, suggests 
that anti-Dkk1 protects from tumor growth by reducing 
MDSC numbers at tumor site, and consequently restoring T 
cell recruitment/activation. In support of this hypothesis, the 
percentage of activated and memory T cells in animals treated 
with an anti-Dkk1 was increased compared with IgG controls.
Very little is known about the regulation of Dkk1 
during tumor progression. Here, we report that LLC and 
B16 tumor cell lines do not express Dkk1 in vitro. However, 
Dkk1 levels are significantly increased in circulation in LLC 
and B16 tumor-bearing mice. Although we can detect Dkk1 
expression at tumor site, Dkk1 mRNA levels in the bone 
are 500-fold higher than in the tumor mass. This finding is 
further supported by the elevated Dkk1 protein levels mea-
sured in the bone microenvironment of tumor-bearing mice 
versus no tumor controls. This observation is very important 
because it supports a prominent role for bone-derived Dkk1 
and indicates that it exerts profound protumor effects, even 
when tumors are located outside the bone. Human studies 
have measured circulating Dkk1 levels, with several showing 
increased Dkk1 expression in circulation and in the primary 
tumors (Yamabuki et al., 2007; Liu et al., 2014). Bone expres-
sion of Dkk1 in cancer patients with no detectable tumors 
in bone has never been evaluated. Future studies will have 
to determine whether bone-derived Dkk1 correlates with 
immune suppression in cancer patients and what are the para-
crine factors that regulate Dkk1 expression in bone when the 
tumor resides outside the bone.
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In conclusion, our study demonstrates that Dkk1 is a 
negative modulator of antitumor immune responses via tar-
geting myeloid suppressor cells in both mice and humans. We 
propose a model whereby an incipient tumor induces the ex-
pression of Dkk1 by bone-resident cells and, to a lesser extent, 
in the primary tumor. Importantly, Dkk1 production by the 
bone microenvironment drives MDSC accumulation during 
tumor progression while Dkk1 expression by the tumor 
stroma might control MDSC recruitment and immune sup-
pressive functions at tumor site.
MAT ERI ALS AND MET HODS
Animals and tumor models. Animals were housed in a patho-
gen-free animal facility at Washington University (St. Louis, 
MO). 6–8-wk-old littermate mice were used in all experi-
ments according to protocols approved by the Institutional 
Animal Care and Use Committee chaired by D.R. Abend-
schein. WT, PLCγ2−/−, and LysM-Cre/β-cateninflox/flox 
(βcatcKo) mice were on C57BL/6 background and were pre-
viously described (Capietto et al., 2013). Nude mice were 
purchased from The Jackson Laboratory. All in vivo figures are 
shown as representative experiments.
LLC (C57BL/6 mouse LLC) and B16 (C57BL/6 
mouse melanoma cells) were cultured at 37°C in complete 
media (DMEM supplemented with 2 mM l-glutamine, 100 
µg/ml streptomycin, 100 IU/ml penicillin, and 1 mM sodium 
pyruvate) containing 10% FBS. To establish tumors, B16 (105) 
and LLC (105) tumor cells were suspended in PBS and inoc-
ulated s.c. in the flank of sex- and age-matched mice. Tumor 
measurements were performed every 2 or 3 d with a caliper 
and volumes were calculated using the following formula: 
V = ½(length [mm] × width [mm] 2).
Antibody neutralization. Anti-Dkk1 neutralizing antibody 
and IgG isotype control were provided by Amgen. Treatment 
consisted of s.c. injections in the flank of mice of anti-Dkk1 
and IgG control at dose of 20 mg/kg three times a week for 
14 d. Anti-Gr1Ab was purchased from Bio X Cell and in-
jected i.p. at a concentration of 12.5 mg/kg three times a 
week for 2 wk. Recombinant mouse Dkk1 protein was pur-
chased from R&D Systems and used at the concentration of 
100 ng/ml for qRT-PCR analysis of β-catenin target genes or 
1 µg/ml for ROS production.
Mouse Dkk1 ELI SA assay. Dkk1 levels from serum and bone 
marrow interstitial fluid of B16 and LLC tumor-bearing mice 
or tumor-free animals were measured by ELI SA according 
to the manufacturer’s instructions (R&D Systems). In brief, 
for measurements of Dkk1 in the bone marrow interstitial 
fluid, tibias and femurs were collected and placed in a plate 
with PBS until all bones were collected. The tibia and femur 
from each leg were then spun in microcentrifuge tubes with 
the tip cut off and placed inside a larger microcentrifuge 
tube to collect the bone marrow. The bone marrow was sus-
pended in 40 µl of PBS and centrifuged at 8,000 RPM for 5 
min to separate the marrow cells from the supernatant, and 
then 10 µl of supernatant from each set of legs were used for 
the ELI SA assay. Final concentration of Dkk1 in the bone 
marrow interstitial fluid was calculated by taking into con-
sideration the volume of PBS used to dilute the bone mar-
row from each set of legs.
Flow cytometric analysis. Immediately upon sacrifice, single- 
cell suspensions were prepared from bone marrow, spleen, and 
tumor. In brief, bone marrow cells were harvested from tibias 
and femurs by centrifugation, whereas spleens were mechan-
ically dissociated and individual cell suspensions were ob-
tained through a 70-µm cell strainer. Tumor tissues were 
minced, and then digested with 3.0 mg/ml collagenase A 
(Roche) and 50 U/ml DNase I (Sigma-Aldrich) in serum 
free media for 30 min at 37°C. Cells were filtered through 
40-µm nylon strainers (Thermo Fisher Scientific), and washed 
twice in PBS with 2% FBS. Red blood cells were then re-
moved with red blood cell lysis buffer (Sigma-Aldrich). Cells 
were washed once and stained in PBS with 0.5% FBS with 
the following anti–mouse antibodies: allophycocyanin (APC)- 
conjugated α-Gr1Ab and eFluor450-conjugated anti-CD44 
(eBioscience), phycoerythrin (PE)-conjugated antibody to 
CD11b, APC-conjugated anti-CD8α, and FITC-conjugated 
anti-CD4 (BD), Brilliant Violet 605 anti-CD62L (BioLeg-
end). The respective isotype-matched conjugated controls 
were purchased from eBioscience and BD, respectively. Cor-
responding isotope controls yielded no significant staining. 
Acquisition was performed on a FAC SCalibur and the dedi-
cated software CellQuest (BD). Data were analyzed with 
FlowJo 7.5.5 software (Tree Star).
MDSC isolation. MDSCs were isolated from bone marrow 
using the Myeloid-Derived Suppressor Cell Isolation kit 
(Miltenyi Biotec), and >95% cell purity was confirmed by 
flow cytometric analysis using anti-CD11b and anti-Gr1. 
When indicated, Gr1+/CD11b+ cells were isolated from 
naive mice and cultured in vitro in medium supplemented 
with 10% serum from tumor-bearing mice, 10 ng/ml 
GMC SF, and 40 ng/ml IL-6.
Human PBMCs from healthy donors were obtained at 
Washington University. In brief, informed consent was pro-
spectively obtained from all the blood donors according to an 
institutionally approved Human Studies Committee Proto-
col. Peripheral blood samples were collected in vacuum tubes 
containing EDTA (BD). PBMCs were isolated by Ficoll- 
density centrifugation and frozen in DMSO with 10% FBS. 
For the experiment, thawed cells were washed and prepared 
for cell isolation using CD33 microbeads with MiniMACS 
columns according to the manufacturer’s protocol (Miltenyi 
Biotec). Purity was confirmed by flow cytometry (>95%). 
RNA isolation was immediately performed.
ROS and NO production. For ex vivo ROS production, 
MDSCs were isolated from LLC tumor-bearing mice treated 
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with anti-Dkk1 neutralizing antibody or IgG control for 14 
d. 105 cells were then incubated for 30 min in the presence of 
oxidation-sensitive dye DCF DA (3 µM). MDSCs were stained 
with anti-Gr1 and CD11b antibodies and ROS production in 
the cells was evaluated FACS analysis.
For in vitro ROS production, 105 Gr1+/CD11b+ cells 
were isolated from naive mice and cultured in RPMI 1640 
supplemented with 10 ng/ml GMC SF + 40 ng/ml IL-6, and 
then stimulated with 1 µg/ml rDkk1 for 24 h in the presence 
of PMA (300 nM; Sigma-Aldrich) for the last 30 min. ROS 
detection by FACS was performed as described above.
For NO levels, 105 MDSCs isolated from tumor-bearing 
mice receiving anti-Dkk1 or IgG antibodies were cultured in 
RPMI 1640 media supplemented with 10 ng/ml GM-CSF + 
40 ng/ml IL-6 and stimulated with 1 µg/ml LPS for 24 h. 
100  µl of culture supernatants were incubated for 10 min 
at room temperature with Greiss reagent (1% sulfanilamide, 
0.1% N-[1-naphthyl]ethyl-enediamine, and 5% H3PO4) to 
measure the nitrite concentrations. The absorbance at 540 nm 
was measured using a microplate reader (Bio-Tek). Nitrite 
concentrations were determined by comparing the absor-
bance values from the samples to a standard curve generated 
by serial dilutions of sodium nitrite (0.25 mM).
T cell suppression assay. Freshly isolated splenocytes (5 × 106 
cells/ml) from WT mice were depleted of red cells with Red 
Blood Cells Lysis Buffer (Sigma-Aldrich) and labeled with 
CFSE (1  µM; Molecular Probes) for 10 min at 37°C and 
washed with fresh culture media. Splenocytes were stimulated 
with anti-CD3 (10 µg/ml) in the presence of WT, PLCγ2−/−, 
or βcatcKo MDSCs isolated from tumor-bearing mice treated 
with anti-Dkk1 or IgG antibodies. Different CFSE-labeled 
splenocyte/MDSC ratios were used (1:10, 1:5, and 1:1). Pro-
liferation of CD8+ T cells, in terms of CFSE dilution, was 
determined by FACS. Data are expressed as the percentage of 
proliferation of stimulated CD8+ CFSE+ T cells. Each exper-
iment was performed in triplicate.
Western blotting. MDSCs isolated from the bone marrow of 
tumor-bearing mice were lysed with RIPA buffer (50 mM 
Tris-HCl, pH 7.4, 150  mM NaCl, 1% NP-40, 0.1% SDS, 
0.5% sodium deoxycholate, 1 mM EDTA, and 10% glycerol) 
supplemented with protease and phosphatase inhibitor cock-
tail (Thermo Fisher Scientific). Equal amounts of total pro-
tein lysates were subjected to 8% SDS-PAGE gel and 
transferred to PVDF membranes. Membranes were blocked 
in 5% BSA in PBS/Tween-20 for 1 h, and then probed with 
the appropriate specific primary antibody overnight at 4°C. 
Membranes were washed and incubated for 2 h at room tem-
perature with secondary antibody-conjugated with peroxi-
dase. Results were visualized by chemiluminescence detection 
using a SuperSignal West Dura Extended Duration Substrate 
(Thermo Fisher Scientific). An antibody against total β- 
catenin was obtained from Cell Signaling Technology. Equal 
loading was assessed using anti–β-actin from Sigma-Aldrich. 
Semi-quantifications of protein were determined using Ge-
neTools software (Syngene).
IHC analysis. Tissue sections from LLC and B16 s.c. tumors 
or pancreas from animals that express an oncogenic form of 
RAS and develop spontaneous pancreatic cancer (KPC mice: 
p48-CRE/Lox-stop-lox KrasG12D/+ p53flox/+) were used 
for Dkk1 IHC analyses. Paraffin sections were deparaffinized 
in serial changes with decreasing ethanol (100, 95, 70, and 
50%), deionized with H2O, and rinsed in PBS. Tissue sec-
tions were submerged in citrate buffer (10 mM sodium ci-
trate and 0.05% Tween 20, pH 6), and antigen retrieval was 
performed in a decloaking chamber (Biocare Medical). The 
sections were washed in running deionized water and rinsed 
in PBS, blocked for 30 min at room temperature in blocking 
buffer (5% normal goat serum, BSA, and PBS), and stained 
with anti-Dkk1 primary antibody (Santa Cruz Biotechnol-
ogy, Inc.; clone H-120; 1:100) diluted in antibody diluent 
overnight at 4°C. The day after washing, a biotinylated sec-
ondary antibody was applied to the slides for 30 min at room 
temperature in a humidified chamber, after SA-HRP incu-
bation (Perkin Elmer) for an additional 30 min. Staining was 
developed using DAB after 3 min of incubation. The tissue 
sections were mounted on coverslips with Vectashield Hard 
Mounting Media (Vector Labs).
Pancreatic cancer TMA cohort and analysis. TMA studies 
were conducted on a patient cohort constructed from 60 
cases of invasive pancreatic ductal adenocarcinoma diag-
nosed at the Department of Pathology, Washington Univer-
sity (Mitchem et al., 2013; Zhu et al., 2014). Patients had not 
received neoadjuvant therapy, and they underwent pancre-
aticoduodenectomy, which was typically followed by adju-
vant chemotherapy. The ethical committee at the Washington 
University School of Medicine approved this study. To as-
semble TMAs, clearly defined areas of tumor tissue were de-
marked on a slide with a fresh tissue section from the paraffin 
block. Two biopsies (1.0 mm diam) were taken from each 
donor paraffin block corresponding to the marked area. For 
immunohistochemical analyses, 4.0-mm paraffin sections 
were used. Fully automated image acquisition was used for 
the results presented in this study. The Aperio ScanScope 
XT Slide Scanner (Aperio Technologies) system was used to 
capture whole slide digital images with a 20× objective. 
Slides were de-arrayed to visualize individual cores using 
Spectrum software (Aperio). CD15+ leukocytes were quan-
titated using a modified nuclear/lymphocyte algorithm in 
the spectrum software, and Dkk1 was quantitated as total 
pixel density. The highest value to each TMA spot was 
assigned to each patient.
Real-time PCR. Total RNA was extracted with TRIzol (In-
vitrogen) and quantified on a ND-1000 spectrophotometer 
(NanoDrop Technologies). The cDNA was synthesized with 
1 µg RNA using RNA to cDNA EcoDry Premix (oligo dT) 
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RT-PCR kit from EMD Millipore. The amount of Dkk1 
was determined using Power SYBR Green mix on 7300 
Real-Time PCR System (Applied Biosystems). Cyclophilin 
mRNA was used as internal control. Specific primers for mice 
were as follows: Dkk1, 5′-CTC ATC AAT TCC AAC GCG 
ATCA-3′ and 5′-GCC CTC ATA GAG AAC TCC CG-3′; 
Cyclophilin, 5′-AGC ATA CAG GTC CTG GCA TC-3′ and 
5′-TTC ACC TTC CCA AAG ACC AC-3′; TCF4, 5′-CGA 
AAA GTT CCT CCG GGT TTG-3′ and 5′-CGT AGC CGG 
GCT GAT TCAT-3′; LEF1, 5′-TGT TTA TCC CAT CAC 
GGG TGG-3′ and 5′-CAT GGA AGT GTC GCC TGA CAG-
3′; Axin2, 5′-ATG TGT GGA TAC GCT GGA CTT-3′ and 
5′-TTC TTG ATG CCA TCT CGT ATG-3′; LRP5, 5′-AAT 
CAA CAA GCC ACC CTC TG-3′ and 5′-GGC TCC ACC 
AAC ATA CTC GT-3′, LRP6, 5′-ACC CTG CAG CAC TGA 
TGT CT-3′ and 5′-GTT CTC CTC CGC TGA CAA GT-3′.
Specific primers for human MDSC were as follows: TCF4, 
5′-CAA GCA CTG CCG ACT ACA ATA-3′ and 5′-CCA GGC 
TGA TTC ATC CCA CTG-3′; LEF1, 5′-AAT GCA CGT GAA 
GCCT-3′ and 5′-GAA TCT GGT TGA TAG CTGC-3′.
Relative quantification of transcription was calculated 
as the power of the difference between amplification of the 
target gene and amplification of Cyclophilin (i.e., 2 −[Ct target 
gene − Ct cyclophilin], where Ct represents threshold cycle).
Statistical analysis. Experiments were done in triplicate 
and analyzed using the Student’s t test. In calculating two-
tailed significance levels for equality of means, equal vari-
ances were assumed for the two populations. In some 
experiments, analysis of variance (ANO VA), including the 
Bonferroni’s multiple-comparison test, was used. Results 
were considered significant at P < 0.05.
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